Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Shanghai 462 Fuzhou 11 Hangzhou 8 Zhengzhou 7 Nantong 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University462 Ruijin Hospital282 Shanghai Zhongshan Hospital169 RenJi Hospital133 Children's Hospital of Fudan University84 Clear sponsor filter
Site location
Shanghai462 Fuzhou11 Hangzhou8 Zhengzhou7 Nantong5
All 53 locations
Target enrolment
to

Trials with a site in Shanghai

462 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Fudan University
Phase 2
46
Shanghai
2027-01-01
Not yet open
Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
NCT07912957Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsTrastuzumab Rezetecan·Adebrelimab
Fudan University
Phase 2
62
Shanghai
2026-11-01
Not yet open
Fudan University
Observational
14
Shanghai
2026-11
Recruiting
Fudan University
Phase 2
220
Shanghai
2026-11
Not yet open
Fudan University
Phase 2
19
Shanghai
2026-10-30
Recruiting
Fudan University
Observational
3,000
Shanghai
2026-10-26
Not yet open
Fudan University
Phase 2
36
Shanghai
2026-10-20
Recruiting
Fudan University
Phase 2
31
Shanghai
2026-10-15
Not yet open
Fudan University
Phase 3
480
Shanghai
2026-10-15
Not yet open
Fudan University
Phase 2
388
Shanghai
2026-10-01
Not yet open
Fudan University
Observational
560
Shanghai
2026-10-01
Not yet open
Fudan University
Phase 2
358
Shanghai
2026-10-01
Recruiting
FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)
NCT07815834Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer, Second-line Treatment, Radiation Therapy
DrugCadonilimab
Fudan University
Phase 3
198
Shanghai
2026-10-01
Not yet open
Fudan University
Phase 2
56
Shanghai
2026-10-01
Recruiting
1-Week Versus 3-Week PBI
NCT07832279Early-Stage Breast Cancer
Fudan University
Not applicable
818
Shanghai
2026-10
Recruiting
Fudan University
Not applicable
534
Shanghai
2026-10
Not yet open
The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07780578Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
DrugsAndamertinib·Anlotinib
Fudan University
Phase 2
34
Shanghai
2026-09-30
Not yet open
Fudan University
Phase 2
180
Shanghai
2026-09-20
Recruiting
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
NCT07841236Colon Cancer, Deficient Mismatch Repair, Microsatellite Instability-High (MSI-H)
Fudan University
Phase 2
23
Shanghai
2026-09-14
Recruiting
Fudan University
Not applicable
534
Shanghai
2026-09-12
Not yet open
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
NCT07825753Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
DrugsMIRV·Mirvetuximab Soravtansine·Trastuzumab emtansine·Enfortumab Vedotin
Fudan University
Phase 2
225
Shanghai
2026-09-10
Not yet open
Fudan University
Phase 2
34
Shanghai
2026-09-01
Recruiting
Fudan University
Phase 2
20
Shanghai
2026-09-01
Not yet open
Fudan University
Phase 2
269
Shanghai
2026-09-01
Not yet open
Fudan University
Phase 2
620
Shanghai
2026-09-01
Recruiting
Fudan University
Phase 2
234
Shanghai
2026-09-01
Not yet open
Fudan University
Phase 2
104
Shanghai
2026-09-01
Not yet open
AI-Assisted Patient Support in mHSPC
NCT07804030Metastatic Prostate Cancer
Fudan University
Not applicable
160
Fuzhou, Shanghai, Kunming, Wenzhou
2026-09
Not yet open
Fudan University
Phase 2
62
Shanghai
2026-08-29
Not yet open
Fudan University
Phase 2
52
Shanghai
2026-08-28
Recruiting
Fudan University
Phase 2
72
Shanghai
2026-08-12
Not yet open
Fudan University
Phase 2
53
Shanghai
2026-08
Not yet open
Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer
NCT07780877Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
Fudan University
Phase 2
85
Changsha, Shanghai
2026-08
Recruiting
Fudan University
Phase 2
148
Shanghai
2026-08
Recruiting
Fudan University
Observational
12,000
Shanghai
2026-07-31
By invitation
Fudan University
Phase 2
16
Shanghai
2026-07-30
Recruiting
Fudan University
Phase 2
140
Shanghai
2026-07-28
Recruiting
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
NCT07647029Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)
Fudan University
Phase 2
126
Shanghai
2026-07-16
Not yet open
Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)
NCT07662863Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Peripheral Neuropathy
DrugSacituzumab tirumotecan
Fudan University
Phase 2
75
Shanghai
2026-07-15
Recruiting
Fudan University
Observational
354
Shanghai
2026-07-15
Active, closed
Fudan University
Observational
200
Shanghai
2026-07-01
Not yet open
Fudan University
Phase 2
189
Shanghai
2026-07-01
Recruiting
Fudan University
Phase 3
636
Shanghai
2026-07-01
Not yet open
Dietary Pattern Intervention for Neurodevelopment in Preterm Infants
NCT07702734Preterm, Neurodevelopmental Disorders, Dysbiosis
Fudan University
Not applicable
116
Shanghai
2026-07-01
Not yet open
Fudan University
Phase 2
36
Shanghai
2026-07
Active, closed
Fudan University
Observational
40
Shanghai
2026-06-30
Not yet open
Fudan University
Phase 1/2
138
Shanghai
2026-06-30
Not yet open
The Effects of Different Anesthetics on the Brain's Neural Networks
NCT07644663Electroencephalogram (EEG), Anesthesia
DrugsEsketamine·Propofol
Fudan University
Phase 4
120
Shanghai
2026-06-09
By invitation
Fudan University
Phase 2
45
Shanghai
2026-06-06
Recruiting
Fudan University
Phase 2
98
Shanghai
2026-06-06
Not yet open
Fudan University
Phase 2
165
Shanghai
2026-06
Not yet open
Probiotics Supplementation for Neurodevelopment in Preterm Infants
NCT07617181Premature Birth, Neurodevelopmental Disorders, Dysbiosis
Fudan University
Not applicable
116
Shanghai
2026-06
Recruiting
Fudan University
Observational
1,000
Shanghai
2026-05-22
Not yet open
Fudan University
Phase 3
420
Shanghai
2026-05-18
Recruiting
Fudan University
Observational
300
Shanghai
2026-05-15
Recruiting
Fudan University
Observational
5,390
Shanghai
2026-05-14
Recruiting
Fudan University
Phase 2
40
Shanghai
2026-05-10
Recruiting
Fudan University
Observational
5,000
Shanghai
2026-05-06
Recruiting
Fudan University
Phase 3
280
Shanghai
2026-05-06
Recruiting
Fudan University
Phase 3
759
Shanghai
2026-05-01
Not yet open
Fudan University
Phase 2
300
Shanghai
2026-05-01
Not yet open
SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer
NCT07551479Locally Advanced Rectal Cancer (LARC), MSS (Microsatellite Stable)
DrugsCapecitabine·Oxaliplatin
Fudan University
Phase 3
612
Shanghai
2026-05-01
By invitation
Anemia on Sublingual Microcirculation in GDFT
NCT07583927Anemia in Patients Undergoing Gastric Cancer Surgery Under Goal-directed Fluid Therapy, Macro-microcirculation Uncoupling
Fudan University
Observational
54
Shanghai
2026-05
Recruiting
Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
NCT07403136Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2
104
Shanghai
2026-04-30
Recruiting
Fudan University
Phase 2
40
Shanghai
2026-04-17
Recruiting
Fudan University
Not applicable
20
Shanghai
2026-04-13
Recruiting
Fudan University
Phase 3
2,288
Shanghai
2026-04-03
Recruiting
Fudan University
Phase 2
53
Shanghai
2026-04-01
By invitation
Fudan University
Observational
44
Shanghai
2026-04-01
Not yet open
Fudan University
Phase 2
37
Shanghai
2026-04
Recruiting
Fudan University
Not applicable
120
Shanghai
2026-03-30
Recruiting
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
NCT06889610Triple Negative Breast Cancer Metastatic, Melanoma Metastatic, Colorectal Cancer Metastatic
Fudan University
Phase 2
95
Shanghai
2026-03-30
Recruiting
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
NCT07300514Maintenance Treatment of Peripheral T-cell Lymphoma
DrugGolidocitinib
Fudan University
Phase 3
136
Shanghai
2026-03-27
Recruiting
Fudan University
Not applicable
66
Shanghai
2026-03-25
Not yet open
Fudan University
Phase 2
30
Shanghai
2026-03-15
Recruiting
Fudan University
Not applicable
1,036
Shanghai
2026-03-15
Recruiting
Fudan University
Phase 2
45
Shanghai
2026-03-11
Recruiting
SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC
NCT07451795Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University
Phase 2
66
Fujian, Shanghai, Xiamen
2026-03-02
Not yet open
Fudan University
Phase 2
300
Shanghai
2026-03-01
Not yet open
Fudan University
Phase 3
248
Shanghai
2026-02-26
Recruiting
Fudan University
Phase 2
116
Shanghai
2026-02-05
Recruiting
Fudan University
Phase 2
58
Shanghai
2026-02-02
Not yet open
Fudan University
Phase 2
114
Shanghai
2026-02-01
Not yet open
Fudan University
Phase 2
48
Shanghai
2026-02
Not yet open
Fudan University
Observational
200
Shanghai
2026-01-31
Recruiting
Fudan University
Phase 2
276
Shanghai
2026-01-29
Not yet open
Fudan University
Phase 4
40
Xuzhou, Shanghai
2026-01-28
Recruiting
Fudan University
Phase 4
110
Shanghai
2026-01-28
Recruiting
Fudan University
Phase 2/3
260
Shanghai
2026-01-25
Recruiting
G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation
NCT07362810Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB), Hematopoetic Stem Cell Transplantation, Hemato-oncologic Patients
DrugG-Csf
Fudan University
Phase 2
224
Fuzhou, Zhengzhou, Nanchang, Shanghai, Hangzhou
2026-01-22
Recruiting
Fudan University
Phase 2
350
Shanghai
2026-01-19
Not yet open
Huaier Granule and Proteinuria
NCT07355361Proteinuria, Breast Cancer Patients
DrugHuaier
Fudan University
Phase 2
120
Shanghai
2026-01-15
Not yet open
Fudan University
Phase 2
38
Shanghai
2026-01-09
Recruiting
Fudan University
Phase 2
100
Shanghai
2026-01-07
Active, closed
MRI-Driven Precision Typing and Response Prediction in Luminal Breast Cancer
NCT07692230HR Positive/HER-2 Negative Breast Cancer
Fudan University
Observational
2,000
Shanghai
2026-01-06
Recruiting
Fudan University
Phase 2
24
Shanghai
2026-01-01
Not yet open
Fudan University
Phase 3
210
Shanghai
2026-01-01
Recruiting
Fudan University
Phase 2
600
Shanghai
2026-01-01
Recruiting
Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
NCT07381738Epstein-Barr Virus-associated Lymphoproliferative Diseases, Chronic Active Epstein-Barr Virus Infection, EBV Associated Lymphoma, Umbilical Cord Blood Transplant
Fudan University
Phase 2
80
Shanghai
2026-01-01
Recruiting
Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC
NCT07290153Breast Cancer Female NOS, General Anxiety Disorder, Depressive Disorder
Fudan University
Observational
120
Shanghai
2026-01-01
Not yet open
AI for Renal Tumors Using Non-Contrast CT
NCT07304492Renal Neoplasms, Renal Cyst
Fudan University
Observational
10,000
Shanghai
2026-01
Not yet open
Fudan University
Phase 2
106
Shanghai
2026-01
Not yet open
Fudan University
Phase 1
66
Shanghai
2025-12-30
Recruiting
ctDNA-guided Treatment Decision-making
NCT07394218Metastatic Breast Cancer ( HER2 Negative), ctDNA
DrugIvonescimab
Fudan University
Phase 2
122
Shanghai
2025-12-24
Recruiting
Fudan University
Not applicable
384
Shanghai
2025-12-15
Not yet open
Fudan University
Not applicable
614
Shanghai
2025-12-15
Not yet open
Fudan University
Observational
16,509
Shanghai
2025-12-10
Recruiting
Fudan University
Not applicable
30
Shanghai
2025-12-09
Recruiting
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
NCT07207824Bladder (Urothelial, Transitional Cell) Cancer, NMIBC
Fudan University
Phase 3
182
Shanghai
2025-12-01
Not yet open
CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer
NCT07268794Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
DrugDocetaxel
Fudan University
Phase 2
112
Shanghai
2025-11-30
Recruiting
Fudan University
Observational
3,000
Shanghai
2025-11-15
Recruiting
Fudan University
Phase 2
73
Shanghai
2025-11-04
Recruiting
Fudan University
Phase 2
126
Shanghai
2025-11-01
Recruiting
Fudan University
Not applicable
90
Shanghai
2025-11-01
Recruiting
T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
NCT07150208Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer
DrugsHLX04·Trastuzumab deruxtecan·Bevacizumab
Fudan University
Phase 2
140
Shanghai
2025-10-20
Active, closed
Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer
NCT07262671NSCLC (Advanced Non-small Cell Lung Cancer)
Fudan University
Observational
100
Shanghai
2025-10-16
Not yet open
Fudan University
Phase 2
104
Shanghai
2025-10-15
Recruiting
Fudan University
Not applicable
120
Shanghai
2025-10-15
Recruiting
Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)
NCT07283575Metastatic Colorectal Cancer ctDNA Surveillance
Fudan University
Observational
497
Shanghai
2025-10-10
Recruiting
The Fever Clinic Acute Respiratory Cohort
NCT07278700Acute Respiratory Infections, Febrile Illnesses, Community-acquired Pneumonia, Viral Respiratory Tract Infections
Fudan University
Observational
1,000
Shanghai
2025-10-10
Not yet open
Fudan University
Phase 2
37
Shanghai
2025-10-10
By invitation
Fudan University
Not applicable
92
Shanghai
2025-10-08
Not yet open
Fudan University
Observational
700
Shanghai
2025-10-01
Recruiting
SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
NCT07182721HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer, SKB264, Inetetamab
DrugsInetetamab·Sacituzumab tirumotecan
Fudan University
Phase 2
48
Shanghai
2025-09-30
Not yet open
Fudan University
Phase 2
30
Shanghai
2025-09-30
Recruiting
Fudan University
Phase 2
60
Shanghai
2025-09-25
Recruiting
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
NCT07152782Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer
DrugsNeratinib·Trastuzumab deruxtecan
Fudan University
Phase 2
202
Shanghai
2025-09-24
Recruiting
Fudan University
Observational
45
Shanghai
2025-09-22
Not yet open
Fudan University
Observational
460
Shanghai
2025-09-15
Not yet open
Fudan University
Phase 2
33
Shanghai
2025-09-15
Not yet open
Fudan University
Observational
418
Shanghai
2025-09-15
Not yet open
Fudan University
Phase 2
288
Shanghai
2025-09-10
Recruiting
Fudan University
Phase 2
30
Shanghai
2025-09-04
Not yet open
De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial
NCT07153757Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Fudan University
Phase 3
2,934
Shanghai
2025-09-01
Recruiting
Fudan University
Phase 1/2
54
Shanghai
2025-09-01
Recruiting
Multicentric Database for Solid Pseudopapillary Neoplasm of the Pancreas
NCT07183280Solid Pseudopapillary Neoplasm of the Pancreas
Fudan University
Observational
2,000
Shanghai
2025-09-01
Recruiting
Fudan University
Observational
250
Shanghai
2025-09-01
Not yet open
Fudan University
Not applicable
210
Shanghai
2025-09-01
Not yet open
Fudan University
Phase 2
36
Shanghai
2025-09-01
Recruiting
Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
NCT07303023Nasopharyngeal Carcinoma (NPC)
Fudan University
Phase 3
462
Shanghai, Hangzhou, Chengdu, Chongqing
2025-09-01
Recruiting
Fudan University
Observational
150
Shanghai
2025-09-01
By invitation
Fudan University
Observational
128
Shanghai
2025-09-01
Not yet open
Fudan University
Phase 4
232
Shanghai
2025-09
Recruiting
Fudan University
Phase 2
138
Shanghai
2025-08-28
Recruiting
Fudan University
Phase 2
56
Shanghai
2025-08-20
Recruiting
Fudan University
Observational
50
Shanghai
2025-08-15
Recruiting
Fudan University
Phase 2
45
Shanghai
2025-08-15
Recruiting
Fudan University
Phase 2
141
Shanghai
2025-08-14
Recruiting
Fudan University
Phase 3
196
Shanghai
2025-08-12
Recruiting
Zhongshan Ketogenic Diet Study 1
NCT07117903Platelet Function and Thrombus Formation
Fudan University
Not applicable
80
Shanghai
2025-08-10
Not yet open
Fudan University
Phase 1/2
20
Anyang, Shanghai
2025-08-01
Recruiting
Fudan University
Phase 2
20
Shanghai
2025-08-01
Not yet open
Fudan University
Not applicable
524
Shanghai
2025-08-01
Recruiting
Fudan University
Phase 2
138
Fuzhou, Anyang, Jinan, Kunming, Shanghai
2025-08-01
Active, closed
Fudan University
Not applicable
160
Shanghai
2025-07-27
Recruiting
Incidence of 107 Lymph Node Metastasis
NCT07165184Esophageal Cancer
Fudan University
Observational
1,100
Shanghai
2025-07-21
Recruiting
Incidence of 106TBL Lymph Node Metastasis
NCT07165210Esophageal Cancer
Fudan University
Observational
1,852
Shanghai
2025-07-21
Recruiting
Fudan University
Phase 3
2,306
Shanghai
2025-07-08
Recruiting
Fudan University
Phase 2
146
Shanghai
2025-07-02
Not yet open
Fudan University
Phase 2
35
Shanghai
2025-07-01
Not yet open
Fudan University
Phase 2
20
Shanghai
2025-07-01
Not yet open
Fudan University
Phase 2
48
Shanghai
2025-06-30
Recruiting
Fudan University
Phase 3
1,903
Shanghai
2025-06-15
Recruiting
Fudan University
Observational
60
Shanghai
2025-06-11
Recruiting
Fudan University
Not applicable
142
Shanghai
2025-06-05
Not yet open
Fudan University
Phase 3
2,508
Shanghai
2025-06-02
By invitation
Fudan University
Observational
60
Shanghai
2025-06-01
Not yet open
Fudan University
Not applicable
531
Shanghai
2025-06-01
Not yet open
Patient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage
NCT06965556Breast Carcinoma, Patient Education, Perioperative Care, Psychological Intervention
Fudan University
Not applicable
1,138
Shanghai
2025-06-01
Recruiting
Fudan University
Observational
300
Shanghai
2025-06-01
Not yet open
Fudan University
Not applicable
1,596
Shanghai
2025-06-01
Not yet open
Fudan University
Not applicable
338
Shanghai
2025-06-01
Recruiting
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
NCT07003022Colo-rectal Cancer, MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
DrugsFruquintinib·Cadonilimab
Fudan University
Phase 2
40
Shanghai
2025-06-01
Recruiting
Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
NCT07705438Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT
Fudan University
Observational
30
Shanghai
2025-05-28
Recruiting
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
NCT06970353Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation, Advanced PDTC or ATC With NRAS Mutation
DrugsPembrolizumab/Finotonlimab·Tunlametinib
Fudan University
Phase 2
40
Shanghai
2025-05-27
Recruiting
Fudan University
Phase 1/2
68
Shanghai
2025-05-26
Recruiting
Fudan University
Observational
100
Shanghai
2025-05-23
Recruiting
Fudan University
Phase 1/2
68
Shanghai
2025-05-13
Recruiting
Fudan University
Phase 1/2
139
Shanghai
2025-05-12
Recruiting
Fudan University
Observational
300
Shanghai
2025-05-09
Recruiting
Fudan University
Phase 2
130
Shanghai
2025-05-08
Not yet open
Fudan University
Phase 2
74
Shanghai
2025-05-01
Not yet open
Active Surveillance for Limited GGNs
NCT06394037Lung Ground-glass Opacities, Active Surveillance
Fudan University
Observational
387
Shanghai
2025-05-01
Not yet open
Fudan University
Phase 3
168
Shanghai
2025-04-28
Recruiting
Fudan University
Phase 2
60
Shanghai
2025-04-25
By invitation
Breast Cancer PET/CT Imaging With 68Ga-pAKTi
NCT06943313Breast Cancers, PIK3CA Mutation-Related Tumors, PI3K Pathway Activated Tumors, PET / CT
Fudan University
Observational
20
Shanghai
2025-04-21
Recruiting
Fudan University
Phase 2
60
Shanghai
2025-04-21
Recruiting
Fudan University
Not applicable
140
Shanghai
2025-04-21
Recruiting
Fudan University
Phase 2
10
Shanghai
2025-04-21
Recruiting
RGL-305+ Lymphoma + Exploratory Clinical Study
NCT07006012Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
Fudan University
Not applicable
12
Shanghai
2025-04-21
Active, closed
A ReaL World Study of DS-8201
NCT06945224Breast Cancer Metastatic, Treatment Efficacy
Fudan University
Observational
300
Shanghai
2025-04-19
Active, closed
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06914687Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis
DrugsTeysuno·Tislelizumab·Docetaxel·Oxaliplatin
Fudan University
Phase 2
30
Shanghai
2025-04-15
Recruiting
Neoadjuvant SNF Precision Therapy Phase III
NCT06913777Neoadjuvant Therapy
DrugFamitinib
Fudan University
Phase 3
404
Shanghai
2025-04-08
Recruiting
Fudan University
Observational
1,500
Shanghai
2025-04-07
Recruiting
Fudan University
Phase 2
100
Shanghai
2025-04-01
Not yet open
Fudan University
Phase 2
120
Shanghai
2025-04-01
Recruiting
Fudan University
Phase 2
30
Shanghai
2025-03-20
Recruiting
Fudan University
Phase 2
164
Shanghai
2025-03-18
Recruiting
Fudan University
Phase 2
92
Shanghai
2025-03-18
Recruiting
Fudan University
Phase 2
221
Shanghai
2025-03-10
Recruiting
Fudan University
Phase 2
44
Shanghai
2025-03-09
Recruiting
Fudan University
Phase 3
182
Shanghai
2025-03-07
Recruiting
Perioperative Immunotherapy for Resectable Limited-Stage SCLC
NCT07109401Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer
DrugTislelizumab
Fudan University
Phase 2
37
Shanghai
2025-03-01
Not yet open
Fudan University
Observational
2,700
Shanghai
2025-03-01
Recruiting
Fudan University
Phase 2
208
Fuzhou, Xiamen, Lanzhou, Zhengzhou, Huaian, Jinan, Taian, Shanghai
2025-03-01
Recruiting
Fudan University
Phase 2
119
Shanghai
2025-02-28
Recruiting
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
NCT06856200Advanced HR - Positive, HER2 - Negative Breast Cancer, Resistant to (Neo)Adjuvant Endocrine Therapy
DrugsSirolimus·Palbociclib·Fulvestrant
Fudan University
Not applicable
36
Shanghai
2025-02-28
Recruiting
Fudan University
Phase 2
36
Shanghai
2025-02-26
Recruiting
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
NCT06849986Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma, Leiomyosarcoma
DrugsLiposomal doxorubicin·Ifosfamide·Tislelizumab
Fudan University
Phase 2
45
Shanghai
2025-02-25
Recruiting
Fudan University
Phase 2
20
Shanghai
2025-02-17
Not yet open
Fudan University
Observational
300
Shanghai
2025-02-15
Recruiting
Fudan University
Phase 2
27
Shanghai
2025-02-15
Not yet open
Fudan University
Phase 2
50
Shanghai
2025-02-15
Recruiting
Fudan University
Phase 3
502
Shanghai
2025-02-12
Recruiting
Reverse HER2-negative Immune Resistant Breast Cancer
NCT06731140HER2 Negative Breast Cancer
Fudan University
Phase 2
10
Shanghai
2025-02-12
Not yet open
Fudan University
Phase 2
80
Shanghai
2025-02-10
Recruiting
Fudan University
Phase 2
34
Shanghai
2025-02-07
Recruiting
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
NCT06793332Triple-Negative Breast Cancer (TNBC), Brain Metastases
DrugsTROP2 ADC·Ivonescimab
Fudan University
Phase 2
39
Shanghai
2025-02-05
Recruiting
A Real World Study of Sacituzumab Govitecan
NCT06966141Breast Cancer Metastatic, Treatment Outcome
Fudan University
Observational
100
Shanghai
2025-02-05
Recruiting
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
NCT06964568Esophageal Carcinoma, Radiotherapy, Immunotherapy
Fudan University
Phase 3
452
Shanghai
2025-02-01
Recruiting
Fudan University
Phase 2
198
Shanghai
2025-01-20
Recruiting
Fudan University
Observational
1,000,000
Shanghai
2025-01-17
Recruiting
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
NCT06775743NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Fudan University
Phase 2
53
Shanghai
2025-01-15
Recruiting
Study on the Mechanism of Acquired Resistance of Entrectinib
NCT07199959ROS1 Fusion Positive, Non Small Cell Lung Cancer
DrugEntrectinib
Fudan University
Observational
38
Shanghai
2025-01-15
Recruiting
Fudan University
Phase 3
1,388
Shanghai
2025-01-09
Recruiting
Fudan University
Phase 1/2
74
Shanghai
2025-01-08
Active, closed
Fudan University
Observational
3,000
Shanghai
2025-01-01
Recruiting
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
NCT06965231Melanoma of Skin, Acral Melanoma, Stage II Melanoma
DrugsEndostar·Toripalimab
Fudan University
Phase 2
58
Shanghai
2025-01-01
Recruiting
Fudan University
Not applicable
16,000
Shanghai
2025-01-01
Recruiting
Fudan University
Phase 2
165
Fuzhou, Shanghai, Tianjin
2025-01-01
Recruiting
Fudan University
Observational
624
Shanghai
2024-12-31
Not yet open
Study of HRS-2189 Combined HRS-5041 in Prostate Cancer
NCT06738745Prostate Cancer Metastatic Disease
DrugsHRS-2189·HRS-5041
Fudan University
Phase 2
90
Shanghai
2024-12-31
Active, closed
Fudan University
Observational
197
Shanghai
2024-12-31
Not yet open
Fudan University
Phase 2
141
Shanghai
2024-12-25
Recruiting
Fudan University
Early Phase 1
38
Shanghai
2024-12-10
Recruiting
Fudan University
Observational
120
Shanghai
2024-12-05
Recruiting
Fudan University
Observational
6,000
Shanghai
2024-12-01
Not yet open
First-line Treatment of Advanced/unresectable DDLPS
NCT06694324Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS)
DrugsLiposomal doxorubicin·Apatinib·Camrelizumab
Fudan University
Phase 2
49
Shanghai
2024-12-01
Active, closed
Fudan University
Not applicable
24
Shanghai
2024-12-01
Recruiting
Fudan University
Observational
1,920
Shanghai
2024-12-01
Not yet open
Fudan University
Phase 2
20
Shanghai
2024-12
Not yet open
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
NCT06731153Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer
DrugsIvarmacitinib·Eribulin·Camrelizumab
Fudan University
Phase 2
40
Shanghai
2024-12
Recruiting
Fudan University
Phase 2
100
Shanghai
2024-11-30
Not yet open
Fudan University
Phase 2
30
Shanghai
2024-11-30
Recruiting
Fudan University
Phase 2/3
50
Shanghai
2024-11-22
Recruiting
Fudan University
Phase 2/3
50
Shanghai
2024-11-22
Recruiting
Ivonescimab in the Treatment of Multiple Advanced Tumors
NCT06683846Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma
Fudan University
Phase 2
400
Shanghai
2024-11-20
Recruiting
Fudan University
Phase 3
250
Shanghai
2024-11-19
Recruiting
Fudan University
Not applicable
9
Shanghai
2024-11-15
Recruiting
Fudan University
Observational
100
Shanghai
2024-11-11
Recruiting
Fudan University
Phase 2
129
Shanghai
2024-11-04
Recruiting
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
NCT06676449Esophageal Carcinoma, Radiotherapy, Immunotherapy
Fudan University
Phase 3
432
Shanghai
2024-11-01
Active, closed
Cola Ingestion for Esophageal Bolus Impaction
NCT06652620Esophageal Cancer
Fudan University
Not applicable
50
Xiamen, Anyang, Yangzhou, Jingdezhen, Shanghai
2024-11-01
Recruiting
Fudan University
Phase 2
340
Shanghai
2024-11-01
Recruiting
Fudan University
Phase 2
80
Shanghai
2024-11-01
Recruiting
Fudan University
Phase 2
340
Shanghai
2024-11-01
Recruiting
Fudan University
Phase 2
22
Shanghai
2024-10-31
Recruiting
Fudan University
Phase 2
33
Shanghai
2024-10-24
Recruiting
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT06649331Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer
DrugsSHR-A1921·SHR-A2009·Famitinib·9MW2821
Fudan University
Phase 2
160
Shanghai
2024-10-21
Recruiting
Fudan University
Phase 4
756
Harbin, Changzhou, Nanjing, Yangzhou, Shanghai, Hangzhou, Ningbo
2024-10-18
Active, closed
Fudan University
Not applicable
40
Shanghai
2024-10-16
Active, closed
Fudan University
Not applicable
40
Shanghai
2024-10-16
Recruiting
Fudan University
Not applicable
40
Shanghai
2024-10-16
Recruiting
Fudan University
Phase 2
160
Shanghai
2024-10-14
Recruiting
Fudan University
Phase 2
60
Shanghai
2024-10-09
Not yet open
Fudan University
Phase 1/2
58
Shanghai
2024-10-01
Active, closed
Fudan University
Phase 2
20
Shanghai
2024-09-30
Recruiting
Fudan University
Observational
800
Shanghai
2024-09-30
Recruiting
Fudan University
Phase 2
130
Shanghai
2024-09-30
Recruiting
Fudan University
Phase 2
116
Shanghai
2024-09-30
Recruiting
Combination of TURP and Standard Systemic Therapy for MPCa
NCT06655259Metastatic Prostate Cancer
Fudan University
Phase 2
200
Shanghai
2024-09-21
Recruiting
Fudan University
Phase 2
76
Shanghai
2024-09-14
Active, closed
Fudan University
Phase 2
50
Shanghai
2024-09-10
Recruiting
Pinoxin for the Prevention of Radiation-Induced Skin Injury
NCT07545720Cancer Patients Undergoning Radiotherapy
Fudan University
Phase 2
202
Shanghai
2024-09-05
Recruiting
Fudan University
Observational
600
Shanghai
2024-09-05
Not yet open
Fudan University
Phase 2
30
Shanghai
2024-09-01
Not yet open
Fudan University
Phase 2
242
Shanghai
2024-09
Not yet open
Fudan University
Phase 2
94
Shanghai
2024-08-31
Recruiting
Fudan University
Phase 4
60
Shanghai
2024-08-19
Recruiting
Fudan University
Phase 2
36
Shanghai
2024-08-15
Recruiting
Fudan University
Phase 2
46
Shanghai
2024-08-13
Recruiting
Fudan University
Phase 2
25
Shanghai
2024-08-12
Active, closed
Fudan University
Phase 2
40
Shanghai
2024-08-07
Recruiting
Fudan University
Phase 1
42
Shanghai
2024-07-31
Recruiting
Fudan University
Observational
48
Shanghai
2024-07-18
Recruiting
Fudan University
Phase 1
9
Shanghai
2024-07-18
Recruiting
Fudan University
Observational
1,000
Shanghai
2024-07-15
Recruiting
Fudan University
Phase 3
124
Shanghai
2024-07-11
Recruiting
Fudan University
Phase 2
74
Shanghai
2024-07-10
Recruiting
Fudan University
Phase 2
52
Shanghai
2024-07-03
Recruiting
Fudan University
Observational
80
Shanghai
2024-07-02
Recruiting
Fudan University
Phase 2
54
Shanghai
2024-07-01
Active, closed
Fudan University
Phase 2
41
Shanghai
2024-07-01
Recruiting
Segmentectomy for Solid-dominant Lung Cancer
NCT06634966Segmentectomy, Lung Adenocarcinoma
Fudan University
Phase 3
277
Shanghai
2024-07-01
Recruiting
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
NCT06494943Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
DrugsCis-platinum·Sintilimab·Paclitaxel
Fudan University
Phase 1/2
27
Shanghai
2024-06-26
Active, closed
Fudan University
Phase 2
58
Shanghai
2024-06-20
Recruiting
Fudan University
Phase 1/2
130
Shanghai
2024-06-17
Active, closed
Fudan University
Phase 3
184
Shanghai
2024-06-11
Recruiting
Fudan University
Phase 2
80
Shanghai
2024-06-01
Recruiting
A Cohort Study in Newly Diagnosed MZL
NCT06449885Marginal Zone Lymphoma
Fudan University
Observational
2,500
Shanghai
2024-05-30
Recruiting
Fudan University
Phase 2
52
Shanghai
2024-05-24
Recruiting
Fudan University
Phase 3
210
Shanghai
2024-05-15
Recruiting
Fudan University
Phase 2
60
Shanghai
2024-05-08
Not yet open
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
NCT06404736Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
DrugsAlbumin-Bound Paclitaxel·Carboplatin
Fudan University
Phase 2
73
Shanghai
2024-05-07
Recruiting
Fudan University
Not applicable
684
Shanghai
2024-05-01
Recruiting
Fudan University
Phase 4
592
Shanghai
2024-05-01
Not yet open
Fudan University
Phase 2
129
Shanghai
2024-05
Not yet open
Fudan University
Phase 1/2
117
Shanghai
2024-04-30
Recruiting
Fudan University
Not applicable
39
Shanghai
2024-04-17
Recruiting
Lymph Node Pathologic Grading Strategy
NCT06745830Lung Adenocarcinoma
Fudan University
Observational
2,998
Shanghai
2024-04-10
Recruiting
Fudan University
Phase 3
172
Shanghai
2024-04-09
Recruiting
Fudan University
Phase 3
1,900
Shanghai
2024-04-02
Recruiting
Primary Tumor Resection for M1a Stage Lung Cancer
NCT06547710Lung Cancer Metastatic, Surgical Resection
Fudan University
Observational
66
Shanghai
2024-04-01
Recruiting
Fudan University
Phase 2
30
Shanghai
2024-04-01
Recruiting
Fudan University
Phase 2
241
Shanghai
2024-04-01
Recruiting
Fudan University
Phase 2
96
Shanghai
2024-04-01
Recruiting
Fudan University
Phase 2
134
Shanghai
2024-04-01
Not yet open
Fudan University
Phase 2
25
Anyang, Shanghai
2024-04-01
Recruiting
Fudan University
Phase 2
192
Shanghai
2024-03-28
Recruiting
Fudan University
Observational
300
Shanghai
2024-03-14
Recruiting
Fudan University
Observational
500
Shanghai
2024-03-12
Recruiting
Fudan University
Phase 3
722
Shanghai
2024-03-10
Recruiting
Fudan University
Phase 2
210
Fuzhou, Nantong, Shanghai, Hangzhou, Ningbo
2024-03-04
Recruiting
Fudan University
Phase 2
30
Shanghai
2024-03-01
Recruiting
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
NCT06228963MALT Lymphoma of Stomach, Helicobacter Pylori Infection
Fudan University
Phase 2
160
Shanghai
2024-03
Recruiting
Fudan University
Observational
80
Shanghai
2024-02-29
Not yet open
Fudan University
Phase 3
524
Shanghai
2024-02-05
Recruiting
Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
NCT06911528Breast Cancer, Sentinel Lymph Node, Frozen Section, Cytology
Fudan University
Not applicable
709
Shanghai
2024-01-30
Recruiting
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
NCT06211790Kidney Cancer, Renal Cell Carcinoma, Renal Clear Cell Carcinoma
Fudan University
Phase 2
66
Shanghai
2024-01-16
Recruiting
Fudan University
Phase 1/2
56
Shanghai
2024-01-15
Recruiting
Fudan University
Phase 2
30
Shanghai
2024-01-10
Recruiting
Fudan University
Phase 4
37
Shanghai
2024-01-05
Recruiting
Fudan University
Phase 1/2
50
Shanghai
2024-01-01
Recruiting
Fudan University
Observational
166
Shanghai
2024-01-01
Recruiting
Fudan University
Phase 2
53
Shanghai
2024-01-01
Not yet open
Fudan University
Early Phase 1
30
Shanghai
2024-01
Recruiting
Fudan University
Phase 2
1,100
Shanghai
2023-12-28
Active, closed
Fudan University
Not applicable
50
Shanghai
2023-12-21
Recruiting
Fudan University
Observational
168
Guangzhou, Shenyang, Shanghai
2023-12-18
Recruiting
Fudan University
Observational
276
Shanghai
2023-12-18
Active, closed
Fudan University
Phase 2
20
Shanghai
2023-12-18
Not yet open
Fudan University
Phase 2
182
Shanghai
2023-12-15
Recruiting
Fudan University
Phase 2
65
Shanghai
2023-12-05
Recruiting
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
NCT06095141Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
DrugCisplatin
Fudan University
Phase 2/3
30
Shanghai
2023-12-01
Recruiting
Fudan University
Phase 3
266
Shanghai
2023-12-01
Recruiting
Fudan University
Not applicable
58
Shanghai
2023-11-20
Recruiting
Surveillance for Multifocal GGNs
NCT06097910Lung Ground-glass Opacities, Active Surveillance
Fudan University
Observational
370
Shanghai
2023-11-01
Active, closed
PET-CT Predicting Lymph Nodes Metastasis
NCT05970913Non Small Cell Lung Cancer, Lymph Node Metastasis, Positron Emission Tomography
Fudan University
Observational
280
Shanghai
2023-11-01
Recruiting
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
NCT06017284Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting
DrugsThalidomide·Nab-paclitaxel·Gemcitabine
Fudan University
Phase 3
100
Shanghai
2023-11-01
Not yet open
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
NCT06102161Lung Cancer, Wedge Resection, Ground-glass Opacity
Fudan University
Phase 3
286
Shanghai
2023-11
Recruiting
Cohort of Twin Pregnancy and the Offspring
NCT05727085Twin Pregnancy
Fudan University
Observational
1,000
Shanghai
2023-10-15
Active, closed
Acute Health Effects of Low Temperature Exposure
NCT06076629Cardiovascular System, Respiratory System, Cognitive Function
Fudan University
Not applicable
50
Shanghai
2023-10-10
Recruiting
Fudan University
Not applicable
160
Shanghai
2023-10-01
Recruiting
Fudan University
Observational
50
Shanghai
2023-10-01
Not yet open
Fudan University
Phase 4
384
Shijiazhuang, Zhengzhou, Changsha, Nantong, Yangzhou, Shanghai, Hangzhou, Jiaxin
2023-10
Recruiting
Fudan University
Phase 2
25
Shanghai
2023-09-13
Recruiting
Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science
NCT06085690CRBSI - Catheter Related Bloodstream Infection, Evidence-based Nursing Practice, Central Venous Catheter Related Bloodstream Infection, Central Venous Catheter Associated Bloodstream Infection
Fudan University
Not applicable
8,050
Shanghai
2023-09-04
Not yet open
Fudan University
Observational
302
Shanghai
2023-09-01
Recruiting
Fudan University
Phase 2
82
Shanghai
2023-08-22
Recruiting
Fudan University
Phase 3
424
Shanghai
2023-08-20
Active, closed
Fudan University
Phase 2
202
Shanghai
2023-08-10
Recruiting
Fudan University
Observational
100
Shanghai
2023-08-01
Recruiting
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
NCT05954078High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation
Fudan University
Phase 3
340
Shanghai
2023-08-01
Recruiting
Fudan University
Phase 2
265
Shanghai
2023-07-26
Active, closed
Fudan University
Phase 2
88
Shanghai
2023-07-26
Recruiting
Fudan University
Phase 2
50
Shanghai
2023-07-20
Recruiting
Fudan University
Phase 2
20
Shanghai
2023-07-20
Active, closed
Fudan University
Phase 2
50
Shanghai
2023-07-10
Not yet open
Fudan University
Not applicable
176
Shanghai
2023-07-01
Recruiting
Postoperative Effects of Different Enterostomy Approaches
NCT05853094Colorectal Cancer, Colorectal Neoplasms Malignant, Intestinal Neoplasms, Malignant
Fudan University
Not applicable
300
Shanghai
2023-06-23
Recruiting
Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer
NCT05904665Non-metastatic Colorectal Cancer, Circulating Tumor DNA Methylation
Fudan University
Not applicable
584
Shanghai
2023-06-15
Recruiting
Fudan University
Phase 3
1,406
Shanghai
2023-06-07
Recruiting
Fudan University
Phase 3
606
Shanghai
2023-06-01
Recruiting
Fudan University
Phase 2
1,008
Shanghai
2023-06-01
Recruiting
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
NCT05901428Hormone Receptor Positive HER-2 Negative Breast Cancer
DrugsEpirubicin·Docetaxel·Cyclophosphamide·Carboplatin
Fudan University
Phase 3
1,736
Shanghai
2023-06-01
Not yet open
Fudan University
Phase 2
47
Shanghai
2023-05-01
Recruiting
Fudan University
Phase 3
134
Shanghai
2023-04-25
Recruiting
Fudan University
Phase 3
634
Shanghai
2023-04-01
Recruiting
Fudan University
Phase 3
390
Shanghai
2023-03-31
Recruiting
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
NCT05749588Triple-negative Breast Cancer
DrugCamrelizumab
Fudan University
Phase 2
120
Shanghai
2023-03-30
Recruiting
Fudan University
Phase 3
223
Shanghai
2023-03-17
Recruiting
The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
NCT07638774Locally Advanced or Metastatic Breast Cancer
Fudan University
Not applicable
324
Shanghai
2023-03-15
Recruiting
Fudan University
Phase 2
25
Shanghai
2023-03-01
Active, closed
Fudan University
Phase 2
145
Shanghai
2023-03-01
Recruiting
Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
NCT05847855Pancreatic Neuroendocrine Tumor, Solid Pancreatic Neoplasms
Fudan University
Observational
1,000
Shanghai, Chengdu
2023-02-27
Recruiting
Fudan University
Phase 3
307
Shanghai
2023-02-15
Recruiting
Fudan University
Phase 2
200
Shanghai
2023-02-01
Recruiting
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
NCT06121700Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer, Oligometastatic Disease
DrugsHerceptin·Trastuzumab
Fudan University
Phase 2
55
Shanghai
2023-01-01
Recruiting
Fudan University
Phase 2
114
Shanghai
2023-01-01
Recruiting
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05594095Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer
DrugsCarrelizumab·SHR-A1921·SHR-A2009·Famitinib
Fudan University
Phase 2
620
Shanghai
2022-12-30
Recruiting
Fudan University
Early Phase 1
24
Shanghai
2022-12-28
Recruiting
Fudan University
Phase 2
34
Shanghai
2022-12-12
Not yet open
A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis
NCT05359393Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis, Microsatellite Stable Colorectal Carcinoma
Fudan University
Phase 2
52
Shanghai
2022-12-01
Recruiting
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT05582499Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC)
DrugsSHR-4602·IBI354·JSKN003·TQB2868
Fudan University
Phase 2
716
Shanghai
2022-11-01
Active, closed
Acute Health Effects of High Temperature Exposure
NCT05575752Cardiovascular System, Respiratory System, Cognitive Function
Fudan University
Not applicable
30
Shanghai
2022-10-23
Recruiting
Fudan University
Phase 2
93
Shanghai
2022-10-18
Recruiting
Fudan University
Not applicable
600
Shanghai
2022-10-01
Recruiting
GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
NCT05575804Advanced/ Metastatic Her-2 Positive Breast Cancer
DrugPyrotinib
Fudan University
Phase 1/2
32
Shanghai
2022-10-01
Recruiting
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
NCT06190782Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy
Fudan University
Phase 3
354
Shanghai
2022-09-27
Active, closed
Fudan University
Phase 2
30
Shanghai
2022-09-10
Recruiting
Fudan University
Not applicable
80
Nanning, Zhengzhou, Changsha, Shanghai, Kunming, Hangzhou
2022-08-25
Recruiting
Fudan University
Phase 1/2
52
Shanghai
2022-08-25
Active, closed
Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)
NCT05306028Pancretic Cancer, Diabete Mellitus
DrugMetformin
Fudan University
Phase 2
20
Shanghai
2022-08-01
Active, closed
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
NCT05468138MSI-H, PD-1 Immunotherapy, Gastric Cancer, Adjuvant Therapy
DrugXelox
Fudan University
Phase 2
94
Shanghai
2022-08-01
Recruiting
Fudan University
Phase 1/2
52
Shanghai
2022-08-01
Recruiting
Fudan University
Phase 2
198
Shanghai
2022-07-02
Recruiting
Fudan University
Phase 2
90
Shanghai
2022-06-30
Active, closed
Fudan University
Not applicable
56
Shanghai
2022-06-09
Active, closed
Effect of FMD on Colorectal Cancer Patients
NCT05384444Fasting Mimicking Diet, Colorectal Cancer
Fudan University
Not applicable
602
Shanghai
2022-06-08
Not yet open
Fudan University
Phase 2
42
Shanghai
2022-05-01
Active, closed
Fudan University
Phase 2
104
Shanghai
2022-03-11
Recruiting
Fudan University
Phase 2
83
Shanghai, Ürümqi
2022-02-26
Recruiting
SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)
NCT04527419Carcinoma, Non-Small-Cell Lung
Fudan University
Not applicable
545
Shanghai
2022-02-09
Recruiting
ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)
NCT03786003Carcinoma, Non-Small-Cell Lung
Fudan University
Not applicable
1,086
Shanghai
2022-02-09
Recruiting
Fudan University
Phase 3
459
Shanghai
2022-01-01
Recruiting
Fudan University
Phase 3
366
Shanghai
2022-01-01
Recruiting
Fudan University
Phase 2
25
Shanghai
2021-10-29
Recruiting
Fudan University
Phase 3
590
Shanghai
2021-10-08
Recruiting
Fudan University
Phase 2
25
Shanghai
2021-09-26
Recruiting
Fudan University
Phase 2
25
Shanghai
2021-09-26
Active, closed
Health Benefits of Air Purifiers in Primary School Students
NCT05016271Cardiopulmonary Function, Child
Fudan University
Not applicable
110
Shanghai
2021-09-22
Recruiting
Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer
NCT05059379Breast Cancer, Radiotherapy; Complications, Effect of Radiation Therapy
Fudan University
Phase 3
1,650
Shanghai
2021-09-20
Recruiting
Fudan University
Observational
139
Shanghai
2021-09-01
Recruiting
Fudan University
Phase 3
300
Shanghai
2021-08-27
Recruiting
Fudan University
Not applicable
225
Shanghai
2021-08-27
Recruiting
Fudan University
Phase 2
25
Shanghai
2021-08-24
Recruiting
Fudan University
Phase 3
433
Shanghai
2021-07-21
Recruiting
Fudan University
Phase 2
25
Shanghai
2021-07-14
Active, closed
Fudan University
Phase 1/2
25
Shanghai
2021-06-09
Recruiting
Fudan University
Observational
510
Shanghai
2021-05-24
Active, closed
Prepectoral and Subpectoral Implant-based Breast Reconstruction
NCT04688697Breast Carcinoma, Breast Reconstruction
Fudan University
Not applicable
300
Shanghai
2021-05-12
Active, closed
Fudan University
Phase 2
98
Shanghai
2021-04-01
Recruiting
Fudan University
Phase 3
2,500
Shanghai
2021-04-01
Recruiting
A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
NCT06749015Metastatic Colorectal Cancer, BRAF V600 Mutation
Fudan University
Observational
100
Shanghai
2021-03-01
Recruiting
Fudan University
Phase 2
70
Shanghai
2021-03-01
Recruiting
Fudan University
Phase 3
508
Shanghai
2021-01-14
Recruiting
Fudan University
Phase 1/2
120
Shanghai
2021-01-01
Recruiting
The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients
NCT05032768Radiation Dermatitis, Skin Microbiome, Breast Cancer, Reconstructive Surgery
Fudan University
Observational
100
Shanghai
2021-01-01
Recruiting
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
NCT06369181Neuroendocrine Carcinoma, Non-small Cell Lung Cancer, Histology Transformation
Fudan University
Observational
50
Shanghai
2021-01-01
Recruiting
Fudan University
Phase 2
51
Shanghai
2020-11-13
Active, closed
Fudan University
Phase 2
100
Shanghai
2020-11-01
Recruiting
Fudan University
Observational
6,000
Shanghai
2020-09-01
Recruiting
Fudan University
Phase 2
25
Shanghai
2020-07-07
Not yet open
Fudan University
Phase 2
222
Shanghai
2020-06-22
Active, closed
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
NCT04764227Esophagus Cancer, Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Radiation Therapy
DrugsPaclitaxel·Carboplatin
Fudan University
Phase 2
70
Shanghai
2020-05-30
Active, closed
Fudan University
Phase 2
367
Shanghai
2020-05-20
Recruiting
Fudan University
Not applicable
94
Shanghai
2020-04-21
Active, closed
Fudan University
Phase 3
808
Shanghai
2020-03-05
Recruiting
Fudan University
Not applicable
320
Nanjing, Shanghai
2020-01-06
Active, closed
Fudan University
Observational
890
Shanghai
2020-01-01
Recruiting
Fudan University
Phase 4
800
Fuzhou, Zhengzhou, Wuhan, Hohhot, Shanghai, Shanxi, Hangzhou, Beijing
2020-01-01
Active, closed
Fudan University
Phase 3
1,560
Shanghai
2019-12-20
Active, closed
Acute Health Effects of Traffic-Related Air Pollution Exposure
NCT04153539Cardiovascular System, Respiratory System
Fudan University
Not applicable
69
Shanghai
2019-10-09
Recruiting
Fudan University
Not applicable
1,528
Shanghai
2019-09-04
Active, closed
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
NCT07491211NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Osimertinib, Stereotactic Radiation
DrugOsimertinib
Fudan University
Observational
300
Shanghai, Wuhan
2019-07-19
Active, closed
MAMMI-BB PET for Monitoring Response to Neoadjuvant Therapy in Breast Cancer
NCT07875244Breast Cancer, Neoadjuvant Therapy, Axilla; Breast
Fudan University
Not applicable
1,024
Shanghai
2019-06-27
Recruiting
Fudan University
Phase 3
1,006
Anqing, Hangzhou, Hefei, Nanchang, Shanghai, Wuhu
2019-01-01
Recruiting
Fudan University
Not applicable
4,052
Guiyang, Suzhou, Dalian, Shanghai
2018-07-01
Recruiting
Fudan University
Not applicable
238
Shanghai
2018-01-10
Recruiting
Fudan University
Phase 3
1,370
Shanghai
2017-05
Active, closed
Fudan University
Phase 2/3
503
Shanghai
2016-01
Recruiting
Fudan University
Observational
500,000
Shanghai
2008-01-01
Rows per page Showing 1–462 of 462
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 462 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

301 of the 462 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 105 have not yet opened recruitment, 48 are active but closed to new participants, and 8 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 462 studies
PhaseStudiesRecruitingShare
Phase 221413146.3%
Observational855818.4%
Not applicable643813.9%
Phase 3604713%
Phase 1/218133.9%
Phase 41062.2%
Phase 2/3541.1%
Early Phase 1320.6%
Phase 1320.6%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Fudan University462301
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.